![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Dong Bang Future Tech & Life Co., Ltd. Hwaseong-si Kr, based in South Korea, is a pharmaceutical company.
One of their significant offerings is Celecoxib, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2015-185 - Rev 00
This Chemical Type CEP, issued on February 14, 2022, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2591 associated with this CEP further emphasizes